Honeywell International Inc vs TransMedics Group Inc — how do they compare? Honeywell International Inc trades at $228.55 (market cap $71.66B), while TransMedics Group Inc trades at $73.86 (market cap $2.54B). The key difference: Honeywell International Inc is far larger — about 28.2× TransMedics Group Inc's market cap, and Honeywell International Inc pays a 4.21% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| HON | TMDX | |
|---|---|---|
Market Cap | $71.66B | $2.54B |
Sector | Industrials | Technology |
52-Week High | $248.04 | $150.42 |
52-Week Low | $188.14 | $61.99 |
Enterprise Value | $96.01B | $2.94B |
Dividend Yield | 4.21% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →